/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./
TSX VENTURE EXCHANGE: AVI
QUEBEC CITY, Aug. 19 /CNW/ - Advitech Inc. ("Advitech") (TSX Venture Exchange: AVI) is pleased to announce that it has entered into an agreement with SEPPIC S.A. ("SEPPIC") for the distribution of subsidiary Botaneco's Hydresia(R) product line in the European personal care market.
"Global expansion is a key component of our value proposition and growth strategy," said Advitech President and CEO Michael Stangel. "We are pleased that SEPPIC will be representing us and anticipate that together, we will significantly grow European sales in line with our objectives."
Dr. Jack Guth, Vice President Research & Development adds that "Hydresia(R) ingredients are uniquely poised to take advantage of a European market where the percent share of natural and organic cosmetics is rising steadily. Oleosomes are EcoCert(R) compliant, have a true sustainability message, and provide a myriad of multi-functional attributes."
Advitech, which includes its subsidiary Botaneco Specialty Ingredients Inc. since November 20, 2009, is a health sciences and technology company developing, manufacturing and marketing proprietary natural ingredients and formulations for oral and topical applications that have been clinically proven to be safe and effective for improving skin health and well being. The Corporation's products are based on three technological platforms which are: i) a superior multi-functional emulsification delivery system derived from plant seed oleosomes for formulation application in the topical cosmetic, OTC, Rx and natural personal care specialty ingredient markets, ii) XP-828L for immune mediated inflammatory disorders, and iii) IM for anti-aging and wound healing. Advitech produces Hydresia(R), a natural plant derived specialty ingredient which offers immediate moisturization advantages, formulating cost savings and excellent product aesthetics in a variety of product applications, Dermylex(R) for the treatment of mild-to-moderate psoriasis, and NudremylTM which acts on skin reconstruction, cellular regeneration and skin structure. More information is available and can be accessed at www.advitech.com and www.botaneco.ca.
SEPPIC, a business within the Air Liquide Healthcare & Hygiene Specialties segment, develops innovative chemical products tailored to meet the needs of the personal care industry. Internationally, SEPPIC operates in 80 countries through a network of agents and distributors in addition to direct presence in 8 countries: France, USA, Germany, China, UK, Italy, Singapore and Brazil. SEPPIC demonstrates a dual expertise in active ingredients and excipients (emulsifiers, rheology modifiers, foaming agents, texturizers, emollients, preservatives). Further information is available at www.seppic.com.
This press release contains forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE ADVITECH INC.
For further information: For further information: Michael Stangel, President and CEO, Advitech Inc., 418-948-4084, 215-604-0631, email@example.com